Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Metabolomx
AddedFeb 16, 2024
UpdatedJun 18, 2026
Metabolomx

Metabolomx

Pre-Seed

Florida-based Metabolomx develops technology for lung cancer detection through breath analysis, rivaling CT scan accuracy.

HQ
West Palm Beach, FL, US
Founded
2010
Overview
Compare
Fundraising
Employees

Metabolomx, based in West Palm Beach, Florida, focuses on developing technology for lung cancer detection through breath analysis. Their system aims to provide a non-invasive, accurate alternative to CT scans, identifying lung cancer subtypes such as small cell, adenocarcinoma, and squamous cell.

In a 2010 trial by the Cleveland Clinic, Metabolomx's first-generation breath analysis system achieved 81% accuracy in detecting lung cancer, comparable to CT scans. This advancement highlights the potential for early, non-invasive cancer diagnosis, significantly impacting patient outcomes.

Metabolomx - Similar Companies

Breath Diagnostics logo

Breath Diagnostics

Matrix-Bio logo

Matrix-Bio

Metabolon logo

Metabolon

metabolon.com

Molecular Biometrics logo

Molecular Biometrics

Diagmetrics logo

Diagmetrics

diagmetrics.com

Micronoma logo

Micronoma

micronoma.com

Nexosome Oncology logo

Nexosome Oncology

Attometrics logo

Attometrics

LungLife AI logo

LungLife AI

lunglifeai.com

Hawkeye Bio logo

Hawkeye Bio

hawkeyebio.com

Biodesix logo

Biodesix

biodesix.com

Metfora logo

Metfora

metfora.com

AxonDx logo

AxonDx

axondx.com

Cleveland Diagnostics logo

Cleveland Diagnostics

clevelanddx.com

Nano Mobile Healthcare logo

Nano Mobile Healthcare

Metabolomx - Quick Facts

Who are Metabolomx's competitors?

Companies similar to Metabolomx include Breath Diagnostics, Matrix-Bio, Metabolon and Molecular Biometrics.

When was Metabolomx founded?

Metabolomx was founded in 2010.

Where is Metabolomx's headquarters located?

Metabolomx's headquarters is located in West Palm Beach, FL, US.

When was Metabolomx's last funding round?

Metabolomx's most recent funding round was for $1.1M (USD) in October 2011.

How much has Metabolomx raised to-date?

As of Oct 24, 2011, Metabolomx has raised a total of $1.1M (USD).

How many employees does Metabolomx have?

Metabolomx has 7 employees as of Feb 4, 2024.

Metabolomx - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Analytics
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Lung Cancer Diagnostics
Tags
  • Biotech
  • Data Information
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified